Breast Cancer – Expert Insights from Aditya Bardia

Expert Interview

Dr Bardia tells us about his early and metastatic breast cancer highlights from ASCO21, including the OlympiA (LBA1), ECOG-ACRIN EA1131 (abstract 605), GeparNUEVO (abstract 506), and VERONICA (abstract 1004) trials, as well as a patient advocate-led survey seeking to understand the views of metastatic breast cancer patients on drug dosing (abstract 1005).
Interviewee: Aditya Bardia
Affiliation(s): Attending Physician, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Disclosures: Consulting or Advisory Role: bioTheranostics, Daiichi Sankyo/Astra Zeneca, Foundation Medicine, Genentech, Genentech/Roche (Inst), Immunomedics, Immunomedics (Inst), Innocrin Pharma (Inst), Merck, Novartis, Novartis (Inst), Pfizer, Pfizer (Inst), Philips, Puma Biotechnology, Radius Health, Radius Health (Inst), Sanofi, Spectrum Pharmaceuticals; Research Funding: AstraZeneca/Daiichi Sankyo (Inst), Genentech (Inst), Immunomedics (Inst), Merck (Inst), Novartis (Inst), Pfizer (Inst), Radius Health (Inst), Sanofi (Inst)
Interview Date: June 9, 2021
Disclaimer: Springer Healthcare selected the experts for interview. The expert interviews appearing herein were not prepared or reviewed by ASCO and have not been subject to a peer review process. The ideas and opinions expressed herein do not necessarily reflect those of ASCO. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions. Read full disclaimer here.
Share:
Share on facebook
Share on twitter
Share on linkedin

Abstracts Referenced In This Expert Interview

Oral Abstract Session

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC)

Presenter: Geoffrey J Lindeman, FRACP, MBBS, PhD
Presentation Date: June 5, 2021
Abstract Number: 1004
Oral Abstract Session

Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC)

Presenter: Anne L Loeser, BS
Presentation Date: June 5, 2021
Abstract Number: 1005
Plenary Session

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer

Presenter: Andrew Tutt, FMedSci, FMedSci, PhD, MBChB
Presentation Date: June 6, 2021
Abstract Number: LBA1
Oral Abstract Session

A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131

Presenter: Ingrid A. Mayer, MD, MSc
Presentation Date: June 4, 2021
Abstract Number: 605
Oral Abstract Session

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)

Presenter: Sibylle Loibl, MD, PhD
Presentation Date: June 6, 2021
Abstract Number: 506

Other Breast Cancer Content

Expert Interview

Breast Cancer – Expert Insights

Dr Harbeck shares her ASCO21 highlights from the early breast cancer track, including the survival data from the ADAPT-HR-/HER2+ study (abstract 503), the first results from the chemotherapy part of the ADAPT-HR+/HER- study (abstract 504), and a subgroup analysis of the monarchE trial of adjuvant abemaciclib (abstract 517).
Interviewee: Nadia Harbeck, MD
Interview Date: June 10, 2021
Oral Abstract Session

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC)

Presenter: Geoffrey J Lindeman, FRACP, MBBS, PhD
Presentation Date: June 5, 2021
Abstract Number: 1004
Oral Abstract Session

Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC)

Presenter: Anne L Loeser, BS
Presentation Date: June 5, 2021
Abstract Number: 1005
Plenary Session

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer

Presenter: Andrew Tutt, FMedSci, FMedSci, PhD, MBChB
Presentation Date: June 6, 2021
Abstract Number: LBA1
Oral Abstract Session

A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131

Presenter: Ingrid A. Mayer, MD, MSc
Presentation Date: June 4, 2021
Abstract Number: 605
Poster Session

Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC)

Presenter: Miguel Martin, MD, PhD
Presentation Date: June 4, 2021
Abstract Number: 517
Oral Abstract Session

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)

Presenter: Sibylle Loibl, MD, PhD
Presentation Date: June 6, 2021
Abstract Number: 506
Oral Abstract Session

Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial

Presenter: Oleg Gluz, MD
Presentation Date: June 6, 2021
Abstract Number: 504
Oral Abstract Session

De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results

Presenter: Nadia Harbeck, MD
Presentation Date: June 6, 2021
Abstract Number: 503
We'd love your feedback!
We'd love your feedback!

Welcome to ASCO Direct™

2021 Annual Meeting Highlights

Expert insights into key ASCO21 data that will impact clinical practice and patient care plus complimentary access to 50 official ASCO video presentations and downloadable slides, picked by our Experts.

ASCO Direct is an officially licensed program of the American Society of Clinical Oncology® (ASCO®)

This program is supported by Bristol Myers Squibb and brought to you by Springer Healthcare